Status:
UNKNOWN
EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Adenocarcinoma of the Prostate
Eligibility:
MALE
18+ years
Brief Summary
The primary objective of this study is to evaluate the predictive value (in terms of remission) of a new technique for detecting circulating, functional, prostate cells among patients with localized a...
Eligibility Criteria
Inclusion
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- Histologically proven presence of prostate adenocarcinoma
- Localized disease on digital rectal examination
- Cancer without extensions
- Acceptance of a curative treatment by the patient
Exclusion
- The patient is participating in another study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection, under tutorship or curatorship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- The patient is taking a hormone-modifying treatment
- Patient taking adrogenic supplements
Key Trial Info
Start Date :
January 3 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
361 Patients enrolled
Trial Details
Trial ID
NCT01402154
Start Date
January 3 2012
End Date
December 1 2021
Last Update
August 5 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, Gard, France, 30029
2
Clinique Beau Soleil
Montpellier, France, 34070
3
CHU de Montpellier - Hôpital Lapeyronie - Plateforme LCCRH
Montpellier, France, 34295
4
CHU de Montpellier - Hôpital Lapeyronie
Montpellier, France, 34295